StockData

Enanta Pharmaceuticals vs Xilio Therapeutics

ENTA and XLO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ENTA and XLO compare

Enanta Pharmaceuticals is the larger company, worth 7.0 times as much as Xilio Therapeutics ($311M against $44.5M).

Xilio Therapeutics keeps more of each dollar of sales as profit, with a net margin of −34.1% compared with −96.9% at Enanta Pharmaceuticals.

Xilio Therapeutics scores higher on the StockData Score (11 against 2 for Enanta Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricENTAXLO
Size and price
Market cap$311M$44.5M
Share price$10.67$7.70
Change, 1 year−9.0%−21.6%
Change, 5 years−88.4%−97.2%
Beta (5Y)1.47−0.00
Employees12076
StockData Score
Total score211 (better)
Valuation score03 (better)
Growth score01 (better)
Performance score12 (better)
Health score15 (better)
Dividend score00
Valuation
P/S4.8×0.7× (better)
P/B3.1×0.6× (better)
FCF yield−11.9% (better)−138%
Fair value$9.66$39.24
Margin of safety−10.5%80.4% (better)
Growth
Revenue growth (TTM)–327%
Revenue growth, 5Y average−11.8%–
Profitability
Operating margin−90.0%−48.9% (better)
Net margin−96.9%−34.1% (better)
FCF margin−56.6% (better)−95.6%
Return on equity−70.1%−55.0% (better)
Financial health
Debt / equity–0.00
Interest coverage−4.5×–
Current ratio3.764.25 (better)
Altman Z-score−1.00 (better)−3.01
Piotroski F-score45 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions93.6%58.9%
Held by insiders7.9%–
Insider net buying, 12 months−$183K$38.3K (better)
Short interest, % of float6.9%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.